NGL Fine-Chem Limited - Asset Resilience Ratio
NGL Fine-Chem Limited (NGLFINE) has an Asset Resilience Ratio of 12.77% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read NGLFINE current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how NGL Fine-Chem Limited's Asset Resilience Ratio has changed over time. See NGLFINE net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down NGL Fine-Chem Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NGL Fine-Chem Limited market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs618.27 Million | 12.77% |
| Total Liquid Assets | Rs618.27 Million | 12.77% |
Asset Resilience Insights
- Moderate Liquidity: NGL Fine-Chem Limited has 12.77% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
NGL Fine-Chem Limited Industry Peers by Asset Resilience Ratio
Compare NGL Fine-Chem Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Roche Holding AG
SW:ROG |
Drug Manufacturers - General | 15.37% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
CSPC Pharmaceutical Group Limited
F:CVG |
Drug Manufacturers - General | 4.64% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.03% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 10.10% |
Annual Asset Resilience Ratio for NGL Fine-Chem Limited (2013–2025)
The table below shows the annual Asset Resilience Ratio data for NGL Fine-Chem Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 13.77% | Rs596.64 Million ≈ $6.45 Million |
Rs4.33 Billion ≈ $46.87 Million |
-1.68pp |
| 2024-03-31 | 15.45% | Rs549.19 Million ≈ $5.94 Million |
Rs3.56 Billion ≈ $38.45 Million |
-0.11pp |
| 2023-03-31 | 15.56% | Rs446.74 Million ≈ $4.83 Million |
Rs2.87 Billion ≈ $31.05 Million |
+5.12pp |
| 2022-03-31 | 10.44% | Rs289.05 Million ≈ $3.13 Million |
Rs2.77 Billion ≈ $29.95 Million |
-4.84pp |
| 2021-03-31 | 15.28% | Rs317.47 Million ≈ $3.43 Million |
Rs2.08 Billion ≈ $22.47 Million |
+6.07pp |
| 2020-03-31 | 9.21% | Rs141.50 Million ≈ $1.53 Million |
Rs1.54 Billion ≈ $16.61 Million |
+0.48pp |
| 2019-03-31 | 8.74% | Rs124.21 Million ≈ $1.34 Million |
Rs1.42 Billion ≈ $15.38 Million |
+1.34pp |
| 2018-03-31 | 7.40% | Rs95.61 Million ≈ $1.03 Million |
Rs1.29 Billion ≈ $13.98 Million |
+2.41pp |
| 2017-03-31 | 4.98% | Rs50.44 Million ≈ $545.44K |
Rs1.01 Billion ≈ $10.95 Million |
+0.97pp |
| 2016-03-31 | 4.01% | Rs31.10 Million ≈ $336.33K |
Rs775.06 Million ≈ $8.38 Million |
+0.89pp |
| 2015-03-31 | 3.12% | Rs20.74 Million ≈ $224.29K |
Rs665.17 Million ≈ $7.19 Million |
+2.38pp |
| 2014-03-31 | 0.74% | Rs4.15 Million ≈ $44.86K |
Rs558.46 Million ≈ $6.04 Million |
+0.65pp |
| 2013-03-31 | 0.09% | Rs424.10K ≈ $4.59K |
Rs473.96 Million ≈ $5.13 Million |
-- |
About NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosph… Read more